New Bill Seeks to Lower Out-of-Pocket Drug Costs

Why It Matters

By ensuring all drug spending reduces deductible and out‑of‑pocket balances, the act could lower financial barriers, improve medication adherence, and stimulate price competition across the prescription‑drug market.

Key Takeaways

• Out‑of‑pocket drug spending would count toward deductibles
• Applies to purchases from any direct‑to‑consumer platform
• Aims to prevent patients from “paying twice” for meds
• Expected to boost competition and lower prescription prices
• Backed by Council for Affordable Health Coverage

Pulse Analysis

The United States continues to grapple with prescription‑drug prices that outpace inflation, leaving many patients to shoulder steep out‑of‑pocket expenses. Direct‑to‑consumer (DTC) platforms such as LillyDirect, NovoCare, Hims & Hers, and Ro have emerged as a workaround, offering lower cash prices by bypassing traditional pharmacy benefit managers. However, most health‑plan benefit designs only credit spending that occurs through designated networks, meaning purchases on DTC sites rarely reduce a patient’s deductible or out‑of‑pocket maximum. This regulatory blind spot creates a “double‑pay” scenario that undermines the cost‑saving promise of DTC channels.

The Every Dollar Counts Act, championed by Rep. Greg Murphy, seeks to close that gap by mandating that any out‑of‑pocket payment for a covered prescription, regardless of the acquisition channel, be applied toward the patient’s deductible and annual out‑of‑pocket limit. By aligning insurance accounting with real‑world spending, the bill could improve medication adherence, lower the effective price of high‑cost therapies, and incentivize insurers to broaden their network definitions. Pharmaceutical manufacturers may also feel pressure to compete on price, knowing that discounts delivered through DTC platforms will now translate into tangible savings for consumers.

Legislative momentum follows the Trump administration’s launch of TrumpRx, a cash‑price marketplace that connects shoppers to manufacturer coupons but stops short of allowing direct purchases. If enacted, the Every Dollar Counts Act would complement such initiatives by ensuring that savings are reflected in insurance calculations, potentially reshaping the pharmacy benefit landscape. Critics warn that insurers could respond by raising premiums or tightening formulary restrictions to offset the broader cost accounting. Nonetheless, the bill’s backing by the Council for Affordable Health Coverage signals growing bipartisan appetite for policies that make life‑saving medicines more financially accessible.